Molecular glue as a new therapeutic strategy in metastatic KRAS-mutant lung cancer @gouthamnarla.bsky.social & team combined a PP2A molecular glue with RAS/MAPK inhibitors to restore tumor-suppressor activity & overcome drug resistance in mice with metastatic KRAS-driven NSCLC: buff.ly/1HzFVe5

Abstract B051: Discovery of SW-3431, a first-in-class molecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers url: aacrjournals.org/mct/article/...

Our new paper describing how mutations to the PP2A gene PPP2R1A drive high-grade uterine cancers is out now in this issue of Cancer Research by @theaacr.bsky.social aacrjournals.org/cancerres/ar...

Molecular Glue Boosts PP2A, Overcoming Resistance to RAS/MAPK Inhibitors in KRAS-Mutant Lung Cancer, Enhancing Survival Rates. by Raines B, Tseng-Rogenski S (...) Narla G et 14 al. in J Clin Invest #MedSky 👉 get more here 📖 read the article: https://www.jci.org/articles/view/193790

Exciting new finding about the role of PP2A molecular glues in overcoming resistant to broad classes of MAPK inhibitors in KRAS driven cancers JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer www.jci.org/articles/vie...